Dr. Reddy's wins Brazil approval for generic semaglutide injection
RDY•Brazil's ANVISA granted Dr. Reddy's marketing authorization for generic semaglutide injections for adults with insufficiently controlled type 2 diabetes. A planned launch with Aché targets a Brazil semaglutide market for diabetes estimated at $244.6 million.
1. Brazil approval
Brazil's ANVISA granted Dr. Reddy's marketing authorization for generic semaglutide injections for adults with insufficiently controlled type 2 diabetes. The planned launch with Aché targets Brazil's semaglutide market for diabetes, estimated at $244.6 million.
